NPS' Norcalcin Shows Potential In HPT

15 January 1996

New data from two clinical trials of NPS Pharmaceuticals' Norcalcin (NPS R-568) suggest that the drug may be a safe and effective treatment for hyperparathyroidism (HPT).

Preliminary analysis of data from a Phase I trial involving 48 healthy men and women over the age of 40, and a Phase I/II study of 20 women with mild, primary HPT, show the drug to reduce plasma concentrations of orthodox HPT markers without causing any serious side effects.

HPT is a disorder characterized by excessive secretion of parathyroid hormone, a trophic factor which causes the release of calcium into the blood, leading to hypercalcemia. Norcalcin is an agonist of a proprietary calcium receptor on parathyroid cells. The drug, mimicking the action of calcium, activates the calcium receptor which in turn causes a homeostatic reduction in the secretion of parathyroid hormone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight